Estonian HealthTech startup Antegenes raises €2.3M to advance personalised cancer prevention

We are glad that investors share our vision of the future of healthcare.Antegenes team has been working for a number of years to help people identify and prevent some of the most difficult chronic conditions all of us are potentially subject to during our lifetime. It takes many years to build a great business and similarly, create a lasting health change and we believe the current milestone gives a boost to Antegenes team to take some exciting steps towards their future, added lead investor Timo Rein.In addition, Antegenes has received two grants to bring research-intensive innovation to international healthcare. The goal of the project is to implement the AnteBC test in breast cancer precision prevention in Estonia, Portugal and Sweden, with further developments in Europe more broadly. By enabling precision prevention with targeted screening, BRIGHT promises to improve patient outcomes and significantly reduce breast cancer mortality. All partners have a strong scientific and clinical background and are acknowledged institutions in the field of oncology both in Norway and internationally.Antegenes products are based on peer-reviewed international research and have been evaluated and validated using anonymous population data from the Estonian Biobank and UK Biobank.Antegenes is an Estonian health technology company and medical laboratory founded in 2018 with a goal to develop and implement advanced genetic tests based on polygenic risk scores technology for precision prevention of major complex diseases.